Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001365 |
Recruitment Status :
Completed
First Posted : December 10, 2002
Last Update Posted : July 13, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease.
Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease.
Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neurodegenerative Disease Parkinson's Disease | Drug: dextromethorphan | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 42 participants |
Primary Purpose: | Treatment |
Official Title: | NMDA Receptor Antagonist Treatment of Neurodegenerative Disease |
Study Start Date : | July 1993 |
Study Completion Date : | June 2001 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Parkinson's disease or other neurodegenerative disorders in which excessive stimulation of central glutamatergic pathways is hypothesized.
Patients must be in good general health and have no history or clinical evidence of significant cardiac (including dysrhythmias), pulmonary, gastrointestinal, renal, hepatic, endocrine, hematological or psychiatric disease.
Patient must not evidence any disorder which in the opinion of the investigator imposes an unnecessary risk to the patient or compromises the scientific interpretation of the data.
Individuals of child bearing potential must practice appropriate methods of birth control.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001365
United States, Maryland | |
National Institute of Neurological Disorders and Stroke (NINDS) | |
Bethesda, Maryland, United States, 20892 |
ClinicalTrials.gov Identifier: | NCT00001365 |
Other Study ID Numbers: |
930183 93-N-0183 |
First Posted: | December 10, 2002 Key Record Dates |
Last Update Posted: | July 13, 2006 |
Last Verified: | July 2000 |
Dextromethorphan Dextrorphan Glutamate Antagonist Parkinson's Disease |
Parkinson Disease Neurodegenerative Diseases Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders |
Excitatory Amino Acid Antagonists Dextromethorphan Antitussive Agents Respiratory System Agents Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |